Title of Invention

NOVEL PHTHALIMIDE AND ISOQUINOLINE DERIVATIVES, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Abstract The present invention is directed to novel thalidomide derivative compounds that have activity as anti-angiogenic compounds. More particularly the compounds have the general structure: where R1 is selected from the group consisting of H, halo, alkyl, haloalkyl, -NH2, hydroxy and alkoxy; R2 is selected from the group consisting of optionally substituted bicyclic, optionally substituted aryl, and R6 is H, or C1-C8 allcyl; R19 is optionally substituted aryl; and m is 0-6.
Full Text NOVEL PHTHALIMIDE AND ISOQUINOLINE DERIVATIVES, AND
PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
Related Applications
This application claims priority under 35 USC §119(e) to US
Provisional Application Serial Nos. 60/285,745, filed April 23, 2001 and 60/338,955,
filed December 10, 2001, the disclosures of which are incorporated herein.
Field of the Invention
The present invention is directed to novel substituted phthalimide and
isoquinoline derivatives, and the use of such derivatives as therapeutic agents. These
compounds have been discovered to have anti-angiogenic activity.
Background of the Invention
Inappropriate angiogenesis is the cause or an aggravating factor in
numerous disease states. For example, age related macular degeneration (ARMD)
refers to a condition that steals away central vision but leaves peripheral (side) vision
intact. This disease can be present in several forms and affects approximately 1 out of
5 individuals over the age of 65 and 1 out of 4 over the age of 75. That represents
approximately 20 million Americans.
There are two forms of macular degeneration: dry macular
degeneration and wet macular degeneration. The dry form, in which the cells of the
macula slowly begin to break down, is diagnosed in 90 percent of macular
degeneration cases. It may occur in one eye or both. The wet form, although it only
accounts for 10 percent of the cases, results in 90 percent of the blindness. As the wet
form worsens, patients begin to have abnormal blood vessels growing behind the
macula. These vessels are very fragile and will leak fluid and blood (hence 'wet'
macular degeneration), causing rapid damage to the macula. As of yet no specific
pharmacological treatments are available.
The wet form of ARMD and other ocular diseases caused by the
formation of new blood vessels (neovascularization) are among the leading causes of
blindness. Thus there is a great need for the discovery of new drugs to treat such
ocular diseases. One approach is to administer pharmaceutical anti-angiogenic agents
to prevent the inappropriate neovascularization.
Novel anti-angiogenic compounds also have utility as anti-cancer
agents. Malignancies are characterized by the growth and spread of tumors. One
important factor in the progression of this disease is angiogenesis, a complex process
in which capillary blood vessels grow in an ordered sequence of events. Once a tumor
has started, every increase in tumor cell population must be preceded by an increase in
new capillaries that converge on the tumor and supply the cells with oxygen and
nutrients. Tumors may thus remain harmless and confined to their tissue of origin, as
long as an accompanying angiogenic program is prevented from being activated.
Since the angiogenesis-dependent step in tumor progression is shared by solid tumors
of all etiologies, the ability to inhibit rumor-associated angiogenesis is a promising
approach in combating cancer.
A substantial body of experimental evidence supports the hypothesis
that tumor angiogenesis is fundamental for the growth and metastasis of solid tumors
[Folkman, J. Natl. Cancer Inst., Vol. 82, pp. 4-6 (1989); N. Weidner, et a!., Amer. J.
Pathol., Vol. 143, pp. 401-409 (1993)]. Indeed, the majority of solid tumors are not
even clinically detectable until after the occurrence of neovascularization, whose
induction in solid tumors is mediated by one or more angiogenic factors.
Furthermore, angiogenesis is also important in a number of other
pathological processes, including arthritis, psoriasis, diabetic retinopathy, chronic
inflammation, scleroderma, hemangioma, retrolental fibroplasia and abnormal
capillary proliferation in hemophiliac joints, prolonged menstruation and bleeding,
and other disorders of the female reproductive system.
Accordingly, there is a need for compounds that have activity as anti-
angiogenic agents and can be safely administered to patients to treat angiogenic-
associated diseases. The present invention relates to a composition, comprising an
anti-angiogenic compound, for use in treating angiogenic-associated diseases, as well
as malignancies, including inhibition of primary tumor growth, tumor progression and
metastasis. More particularly, the present invention is directed to thalidomide
derivatives and their use as anti-angiogenic compositions.
Thalidomide was originally prescribed as a sedative, however its use
was discontinued when it was found to be a potent teratogen, causing serious birth
defects, especially affecting limb development. The dysmelia (limb defects) seen with
thalidomide is proposed to be caused by an inhibition of blood vessel growth in the
developing fetal limb bud. Although this affect is vasculogenic (affecting the
formation of a capillary bed), studies have demonstrated that thalidomide is also anti-
angiogenic (affecting the formation of new blood vessels from sprouts of pre-existing
vessels). Thalidomide is relatively nontoxic, when taken by nonpregnant adults and is
now in phase 2 clinical trials as a potential anti-cancer agent as well as a treatment for
vascular eye diseases such as diabetic retinopathy, retinopathy of prematurity, and
macular degeneration.
Thalidomide has been reported by Folkman, et. al. (PNAS, 91(9):4082-
5, 1994) as having significant anti-angiogenic efficacy. The effects of thalidomide on
corneal angiogenesis induced by vascular endothelial growth factor (VEGF), has been
reported (Kruse et al, Graefes Archive for Clinical & Experimental Ophthalmology.
236(6):461-6, 1998). In Kruse et al, corneal neovascularization was induced in
rabbits by an intrastromal pellet loaded with 500 or 750 ng VEGF. Animals receiving
two daily feedings of 200 mg/kg of thalidomide, responded with statistically
significant inhibition (P treatment. This observation indicates that thalidomide has a significant anti-
angiogenic effect against VEGF-induced ocular neovascular growth.
Thalidomide has also demonstrated inhibitory effects on angiogenesis
in the basic fibroblast growth factor (bFGF) induced rabbit corneal micropocket assay
and orally in mice models (Joussen et al. Graefes Archive for Clinical & Experimental
Ophthalmology, 237(12):952-61, 1999 and Kenyon et al., Experimental Eye Research.
64(6):971-8, 1997). Thalidomide and a thalidomide analog (cc-1069) have been
reported to inhibit the in vitro proliferation of endothelial cells, (cells which make up
the vascular system). The results of this study revealed a significant decrease in
endothelial cell proliferation in cultures treated with thalidomide and/or cc-1069.
Taken together, these data support a strong correlation between the anti-angiogenjc
potential and inhibition of endothelial cell proliferation for thalidomide.
Studies reveal that the S(-)-enantiomer of thalidomide has the strongest
anti-angiogenic activity in both VEGF-induced and bFGF-induced corneal
neovascularization. This enantioselective preference lends support to a possible
receptor mediated mechanism. The present invention is directed to a novel series of
thalidomide analogs and the use of such analogs as inhibitors of angiogenesis. More
particularly, the thalidomide analogs of the present invention lack the piperidine-2,6-
dione moiety of thalidomide.
Summary of the Invention
The present invention is directed to a compound represented by a general structure
selected from the group consisting of:
wherein R1 is selected from the group consisting of H, halo, C1-C4 alkyl, carboxy
and C1-C8 alkoxy;
R3 is selected from the group consisting of
R4 is selected from the group consisting of H, C1-C8alkyl, phenyl and benzyl;
R8 is selected from the group consisting of H, C1-C8 alkyl, phenyl and benzyl or R3
and R8 taken together, can form, with the adjacent ring, a 5- or 6-membered heteroaryl;
R10 and R11 are independently selected from the group consisting of H, halo, C1-C8
alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11 taken together,
can form with the adjacent ring, a C5-C6 cycloalkyl or C5-C6 aromatic ring;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, or C1-C12 alkyl, C2-C8 alkenyl and
C2-C8 alkynyl; and m is an integer ranging from 0-6.
Detailed Description of the Invention
Definitions
In describing and claiming the invention, the following terminology
will be used in accordance with the definitions set forth below.
As used herein, the term "purified" and like terms relate to the isolation
of a molecule or compound in a form that is substantially free of contaminants
normally associated with the molecule or compound in a native or natural
environment.
As used herein, the term "treating" includes prophylaxis of the specific
disorder or condition, or alleviation of the symptoms associated with a specific
disorder or condition and/or preventing or eliminating said symptoms.
As used herein, the term "halogen" or "halo" means Cl, Br, F, and I.
Especially preferred halogens include Cl, Br, and F. The term "haloalkyl" as used
herein refers to a C1 -C4 alkyl radical bearing at least one halogen substituent, for
example, chloromethyl, fluoroethyl or trifluoromethyl and the like.
The term "C1 -C4 alkyl" wherein n is an integer, as used herein,
represents a branched or linear alkyl group having from one to the specified number of
carbon atoms. Typically C1 -C6 alkyl groups include, but are not limited to, methyl,
ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the
like.
The term "C2 -C8 alkenyl" wherein n is an integer, as used herein,
represents an olefinically unsaturated branched or linear group having from 2 to the
specified number of carbon atoms and at least one double bond. Examples of such
groups include, but are not limited to, 1-propenyl, 2-propenyl, 1,3-butadienyl, 1-
butenyl, hexenyl, pentenyl, and the like.
The term "C2 -C8 alkynyl" wherein n is an integer refers to an
unsaturated branched or linear group having from 2 to the specified number of carbon
atoms and at least one triple bond. Examples of such groups include, but are not
limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.
The term "C3-C8 cycloalkyl" wherein n is an integer refers to cyclic
non-aryl group, for example C3-C8 cycloalkyl, represents cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "lower alky!" as used herein refers to branched or straight
chain alkyl groups comprising one to eight carbon atoms, including methyl, ethyl,
propyl, isopropyl, n-butyl, t-butyl, neopentyl and the like.
As used herein, the term "optionally substituted" refers to from zero to
four substituents, wherein the substituents are each independently selected. Each of
the independently selected substituents may be the same or different than other
substituents.
As used herein the term "aryl" refers to a mono- or bicyclic carbocyclic
ring system having one or two aromatic rings including, but not limited to, phenyl,
benzyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. "Optionally
substituted aryl" includes aryl compounds having from zero to four substituents, and
"substituted aryl" includes aryl compounds having one to three substituents, wherein
the substituents, including alkyl, halo or amino substituents. The term (C5-C8
alkyl)aryl refers to any aryl group which is attached to the parent moiety via the alkyl
group.
The term "heterocyclic group" refers to a mono- or bicyclic carbocyclic
ring system containing from one to three heteroatoms wherein the heteroatoms are
selected from the group consisting of oxygen, sulfur, and nitrogen.
As used herein the term "heteroaryl" refers to a mono- or bicyclic
carbocyclic ring system having one or two aromatic rings containing from one to three
heteroatoms and includes, but is not limited to, furyl, thienyt, pyridyl and the like.
The term "bicyclic" represents either an unsaturated or saturated stable
7- to 12-membered bridged or fused bicyclic carbon ring. The bicyclic ring may be
attached at any carbon atom which affords a stable structure. The term includes, but is
not limited to, naphthyl, dicyclohexyl, dicyclohexenyl, and the like.
As used herein, the term "pharmaceutically acceptable carrier"
encompasses any of the standard pharmaceutical carriers, such as a phosphate
buffered saline solution, water and emulsions such as an oil/water or water/oil
emulsion, and various types of wetting agents.
As used herein, "effective amount" means an amount sufficient to
produce a selected effect. For example, an effective amount of the phthalimide
derivative is an amount of the compound sufficient to decrease endothelial cell
proliferation, or decrease the growth rate of blood vessels, either in vivo or in vitro.
The term, "parenteral" means not through the alimentary canal but by
some other route such as subcutaneous, intramuscular, intraspinal, or intravenous.
As used herein, the term "angiogenesis" means the generation of new
blood vessels into a tissue or organ.
As used herein, the term "angiogenic-associated" disease or condition
refers to a disease state or condition that is caused by, or aggravated by, inappropriate
or excessive ageogenesis. For example, diseases that are considered angiogenic-
associated include cancer as well as vascular eye diseases such as diabetic retinopathy,
retinopathy of prematurity, and macular degeneration
Compounds of the present invention that have one or more asymmetric
carbon atoms may exist as the optically pure enantiomers, or optically pure
diastereomers, as well as mixtures of enantiomers, mixtures of diastereomers, and
racemic mixtures of such stereoisomers. The present invention includes within its
scope all such isomers and mixtures thereof.
The Invention
The present invention relates a novel series of substituted phthalimide
and isoquinoline derivatives that are anticipated to have anti-angiogenic activity.
More particularly, the invention is directed to a series of thalidomide derivatives
wherein the piperidine-2,6-dione moiety has been replaced with other structures as
shown below:
In accordance with one embodiment a novel compound is provided
having a general structure selected from the group consisting of:
wherein R1 is selected from the group consisting of H, halo, C1-C8 alkyl, C1-C8
haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy;
R2 is selected from the group consisting of optionally substituted bicyclic,
optionally substituted aryl, and
R3 is selected from the group consisting of
Rg is selected from the group consisting of H, C1-C8 alkyl, or R3 and R8 taken
together, can form, with the adjacent ring, an optionally substituted 5- or 6-membered
aromatic ring;
R10 and R11 are independently selected from the group consisting of H, halo,
C1-C8 alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11 taken
together, can form, with the adjacent ring, an optionally substituted 5- or 6-membered
aromatic ring;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, or C1-C12 alkyl, C1-C8 alkenyl
and C2-C8 alkynyl;
n is an integer ranging from 0-2; and m is an integer ranging from 0-6.
In accordance with one embodiment the anti-angiogenic compound has
the general structure:
wherein R, is selected from the group consisting of H, halo, C1-C4 alkyl,
carboxy and C1-C8 alkoxy;
R2 is selected from the group consisting of
R8 is selected from the group consisting of H, C1-C8 alkyl, or R3 and R8 taken
together, can form, with the adjacent ring, an optionally substituted 5- or 6-membered
heteroaryl;
R4 is selected from the group consisting of H, C1-C8 alkyl, phenyl and benzyl;
R13 and R9 are independently selected from the group consisting of H, halo and
C1-C8 alkoxy or R13 and R9 taken together, can form with the adjacent ring, an
optionally substituted C5-C6 cycloalkyl or optionally substituted C5-C6 aromatic ring;
R10 and R11 are independently selected from the group consisting of H, halo,
C1-C8 alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or Rl0 and R11 taken
together, can form with the adjacent ring, an optionally substituted C5-C6 cycloalkyl or
an optionally substituted C5-C6 aromatic ring;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, or C1-C12 alkyl, C2-C8 alkenyl
and C2-C8 alkynyl;
R12 is selected from the group consisting of H, halo, C1-C4 haloalkyl, -NR5R6,
C1-C8 alkyl, hydroxy and C1-C8 alkoxy;
n is and integer from 1-3 and m is an integer ranging from 0-6. In one
embodiment, R1, R4 and R8 are each H, n is 1 and m is 0.
In accordance with one embodiment the anti-angiogenic compound has
the general structure:
wherein R, is selected from the group consisting of H, halo, C1-C8 alkyl,
hydroxy and C1-C8 alkoxy and R3 is selected from the group consisting of
wherein R6 is H, or C1-C8 alkyl; R10 and R11 are independently selected from the group
consisting of H, halo, C1-C8 alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8
alkoxy, or R10 and R11 taken together, can form with the adjacent nng, an optionally
substituted C1-C6 cycloalkyl or C5-C6 aromatic ring; R5 and R7 are independently H, or
C1-C8 alkyl; and m is an integer ranging from 0-6. In one embodiment, R1 is H and R3
is selected from the group consisting of phenyl;
wherein R6 is H, or C1-C8 alky!; R10 and R11 are independently selected from
the group consisting of H, halo, C1-C8 alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and
C1-C8 alkoxy and R5 and R7 are independently H, or C1-C8 alkyl.
In accordance with one embodiment the anti-angiogenic compound has
the general structure:
wherein R1 is selected from the group consisting of H, halo, C1-C8 alkyl, hydroxy and
C1-C8 alkoxy; and
R2 is selected from the group consisting of
wherein Rl0 and R11 are independently selected from the group consisting of H,
halo, C1-C8 alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11
taken together, can form with the adjacent ring, an optionally substituted C5-C6
cycloalkyl or optionally substituted C5-C6 aromatic ring;
m is an integer ranging from 0-3;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, C1-Cl2 alkyl, C2-C8 alkenyl and
C2-C8 alkynyl;
Rl2 is selected from the group consisting of H, halo, C1-C4 haloalkyl, -NR5R6,
C1-C8 alkyl, hydroxy and C1-C8 alkoxy; and
n is an integer ranging from 1-3.
In one embodiment the compound of the present invention has the
general structure:
wherein R2 is selected from the group consisting of
wherein R10 and R11 are independently selected from the group consisting of H, halo,
C1-C4 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy; and
R5 and R7 are independently H, or C1-C4 alkyl;
R12 is selected from the group consisting of H, halo and C1-C8 alkoxy; and
R6 is C1-C6 alkyl. In one preferred embodiment R2 is selected from the group
consisting of
wherein R10 and R11 are independently selected from the group consisting of H, halo,
and C1-C8 alkoxy.
In one preferred embodiment the compound has the structure:
wherein R6 is C1-C8 alkyl and R10 and R11 are independently selected from the group
consisting of H and C1-C4 alkoxy, or Rl0 and R11 taken together, can form, with the
adjacent ring, an optionally substituted 5- or 6-membered aromatic ring.
One aspect of the present invention is directed to a method of treating a
angiogenic-associated disease or condition. More particularly, one embodiment of the
present invention is directed to inhibiting undesired angiogenesis in a warm-blooded
vertebrate, including humans. The method comprises the step of administering to the
human or animal a composition comprising an effective amount of a compound of the
general structure:
wherein R, is selected from the group consisting of H, halo, C1-C8 alkyl, C1-C8
haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy;
R2 is selected from the group consisting of optionally substituted bicyclic,
optionally substituted aryl, and
R3 is selected from the group consisting of
Rg is selected from the group consisting of H and C1-C8 alkyl, or R3 and R8
taken together, can form with the adjacent ring, an optionally substituted 5- or 6-
membered aromatic ring;
R10 and R11 are independently selected from the group consisting of H, halo,
C1-C8 alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11 taken
together, can form, with the adjacent ring, an optionally substituted C5-C6 cycloalkyl
or an optionally substituted C5-C6 aromatic ring;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, or C1-C8 alkyl, C2-C8 alkenyl
and C2-C8 alkynyl;
n is an integer ranging from 0-2; and m is an integer ranging from 0-6.
In one embodiment a method of inhibiting angiogenesis comprises
administering a compound having the general structure :
wherein R, is H, halo or C1-C4 haloalkyl;
R2 is selected from the group consisting of
wherein R10 and R11 are independently selected from the group consisting of H,
halo, C1-C4 haloalkyt, -NR5R7, hydroxy and C1-C8 alkoxy;
R5 and R7 are independently H, or C1-C4 alkyl;
R12 is selected from the group consisting of H, halo and C1-C8 alkoxy; and
R6, is C1-C8 alkyl. In one embodiment R10 and R11 are independently H, halo or
C1-C4 alkoxy, R1 and Rl2 are H, and R6 is C1-C6 alkyl.
In accordance with one embodiment the thalidomide derivative
compounds of the present invention can be formulated as pharmaceutical
compositions by combining the compounds with one or more pharmaceutically
acceptable carriers. These formulations can be administered by standard routes. In
general, the combinations may be administered by the topical, transdermal, oral, rectal
or parenteral (e.g., intravenous, subcutaneous or intramuscular) route. In addition, the
combinations may be incorporated into biodegradable polymers allowing for sustained
release of the compound, the polymers being implanted in the vicinity of where drug
delivery is desired, for example, at the site of a tumor. Biodegradable polymers
suitable for use with the present invention are known to the skilled practitioner and
are described in detail, for example, in Brem et al., J. Neurosurg. 74:441-446 (1991).
In addition to the use of such pharmaceutical compositions as anti-
angiogenic compounds, the thalidomide derived compounds and corresponding
compositions also have utility as sodium channel blockers, calcium channel blockers,
contraceptives, anti-inflammatory agents and anti-cancer agents. In one embodiment
a composition comprising a thalidomide derivative of the present invention is used to
treat age related macular degeneration.
In accordance with one embodiment the present composition are
administered either orally or parenterally. When administered orally, the compounds
are administered as a liquid solution, powder, tablet, capsule or lozenge. The
compounds can be used in combination with one or more conventional
pharmaceutical additives or excipients used in the preparation of tablets, capsules,
lozenges and other orally administrable forms. When administered parenterally, and
more preferably by intravenous injection, the derivatives of the present invention can
be admixed with saline solutions and/or conventional IV solutions.

The dosage of the active compound will depend on the condition being
treated, the particular compound, and other clinical factors such as weight and
condition of the human or animal and the route of administration of the compound. It
is to be understood that the present invention has application for both human and
veterinary use. For oral administration to humans, a dosage of between approximately
0.1 to 300 mg/kg/day, preferably between approximately 0.5 and 50 mg/kg/day, and
most preferably between approximately 1 to 10 mg/kg/day, is generally sufficient.
It should be understood that in addition to the active anti-angiogenic
compounds, the compositions of the present invention may include other agents
conventional in the art including solubilizing agents, inert fillers, diluents, excipients
and flavoring agents.
In accordance with one embodiment, diseases associated with corneal
neovascularization can be treated by administering a composition comprising a
compound having the general structure:
wherein R1 is selected from the group consisting of H, halo, alkyl, haloalkyl,
-NR5R6, hydroxy and alkoxy;
R2 is selected from the group consisting of
R8 is selected from the group consisting of H and alkyl, or R3 and R8 taken
together, can form with the adjacent ring, an optionally substituted C5-C6 cycloalkyl or
C5-C6 aromatic ring;
R10 and R11 are independently selected from the group consisting of H, halo,
C1-C4 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11 taken together, can
form with the adjacent ring, an optionally substituted C5-C6 cycloalkyl or optionally
substituted C5-C6 aromatic ring;
R5 and R7 are independently H, or C1-C4 alkyl;
RI2 is selected from the group consisting of H, halo and C1-C8 alkoxy;
m is an integer ranging from 0-4; and
R6 is C1-C8 alkyl. In one embodiment the compound has the general structure
wherein R1 is H or halo; and
R2 is selected from the group consisting of
wherein R10 and R11 are independently H, halo or C1-C4 alkoxy, R1 and Rl2 are
H, and R6 is C1-C6 alkyl.
Another disease which can be treated according to the present
invention is rheumatoid arthritis. It is believed that the blood vessels in the synovial
lining of the joints undergo angiogenesis. In addition to forming new vascular
networks, the endothelial cells release factors and reactive oxygen species that lead to
pannus growth and cartilage destruction. The factors involved in angiogenesis may
actively contribute to, and help maintain, the chronically inflamed state of rheumatoid
arthritis.
The thalidomide derived compounds of the present invention are also
anticipated to have use in treating a wide variety of diseases or conditions that are
related to angiogenesis, including diabetic retinopathy, retinopathy of prematurity,
corneal graft rejection, neovascular glaucoma and retrolental fibroplasia, epidemic
keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis,
superior limbic keratitis, pterygium keratitis sicca, sjogrens, acne rosacea,
phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical bums,
bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections,
protozoan infections, Kaposi sarcoma, Mooren ulcer, Terrien's marginal degeneration,
mariginal keratolysis, trauma, rheumatoid arthritis, systemic lupus, polyarteritis,
Wegeners sarcoidosis, Scleritis, Steven's Johnson disease, pemphigoid radial
keratotomy, and corneal graph rejection. Diseases associated with retinal/choroidal
neovascularization that can also be treated according to the present invention and
include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell
anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Pagets disease, vein occlusion,
artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacteria!
infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity,
Eales disease, Bechets disease, infections causing a retinitis or choroiditis, presumed
ocular histoplasmosis, Bests disease, myopia, optic pits, Stargarts disease, pars
planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma
and post-laser complications.
Example 1
Molecular modeling was used to facilitate the design of a novel series
of isoquinolines. Initially, a one carbon addition to the imide ring was considered to
prepare compounds of the general structure:
Conformational analysis of this phthalimide analog, docked in the crystal structure of
polyADP-ribose polymerase, revealed the conformational similarity of the proposed
structural mimic with phthalimides. With this in mind, the synthesis of two initial
series of analogs was proposed as a preliminary set of synthetic targets.
These compounds represent first generation analogs which investigate important
structure and enantioselective relationships for isoquinolines. The synthesis of
mimics 1-10 is outlined in Scheme 1 and represents reasonable literature reported
organic transformations. The utility of this synthetic scheme allows for the insertion
of a large diversity of functional groups. Furthermore the synthetic design allows for
the straightforward synthesis of enantiomerically pure final products through the
addition of selected chiral amino acids.
Scheme I. Synthetic Scheme for Analogs in this Study
Example 2
Additional compounds were prepared wherein the piperidine-2,6-dione moiety
of thalidomide is replaced with a rigid or open ring structure having the general
structure:
wherein R22 is aryl and R23 is H, C1-C12 alkyl, C2-C12 alkenyl or C2-Cl2 alkynyl, or R22
and R23 together with the intervening carbons form an aryl. The synthetic schemes
used to prepare these compounds is as follows:
Synthesis of 2-Indan-5-yl-l,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid
These compounds will be evaluated for their ability to inhibit corneal
neovascularization and endothelial cell proliferation.
Example 3
Endothelial cell proliferation assay.
The human vascular endothelial cells (HUVECS) were cultured to
peri-confluence (80%) in 20% serum and treated with thalidomide (standard) or its
analog (40-400 µM). After 20 h, [3H]-thymidine (2 µCi/ml) was added to the culture
medium for 2-4 h. The [3H]-thymidine incorporation was stopped with ice-cold PBS
(3 washes) and the cells were incubated with cold 10% trichloroacetic acid (TCA) for
10 min at 4ºC. The cells were further incubated with TCA at room temperature for
10 mm and washed three times with PBS. The cells were solubilized overnight with
1N NaOH and neutralized with an equivalent amount of 1N HC1 before radioactivity
was determined. The anti-proliferative activity of thalidomide or its analog was
computed as a percent inhibition of HUVECS mitogenic response to 20% serum (fetal
calf serum).
Evaluation of thalidomide for inhibition of the incorporation of 3H-
thymidine into endothelial cells reveal this compound to have an IC50 of 200 µM.
Preliminary IC50 data for the first panel of compounds reveal four compounds (5, 29,
32 and 50) to have 2-4 times greater potency than thalidomide in inhibiting 3H-
thymidine incorporation into endothelial cells (See Table 1). This structure activity
relationship (SAR) establishes that the piperidine-2,6-dione moiety is not needed for
increased inhibition of endothelial cell proliferation.
Example 4
4-oxo-quinazoline derivatives having the general structure:
WE CLAIM:
1. A compound represented by a general structure selected from the group consisting
of:
wherein R1 is selected from the group consisting of H, halo, C1-C4 alkyl, carboxy
and C1-C8 alkoxy;
R3 is selected from the group consisting of
R4 is selected from the group consisting of H, C1-C8alkyl, phenyl and benzyl;
R8 is selected from the group consisting of H, C1-C8 alkyl, phenyl and benzyl or R3
and R8 taken together, can form, with the adjacent ring, a 5- or 6-membered heteroaryl;
R10 and R11 are independently selected from the group consisting of H, halo, C1-C8
alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11 taken together,
can form with the adjacent ring, a C5-C6 cycloalkyl or C5-C6 aromatic ring;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, or C1-C12 alkyl, C2-C8 alkenyl and
C2-C8 alkynyl; and m is an integer ranging from 0-6.
2. The compound as claimed in claim 1, wherein
R1 is H or halo;
R3 is selected from the group consisting of
R4 and R8 are H;
R6 is C1-C8 alkyl;
R10 and R11 are independently selected from the group consisting of H, halo, and
C1-C8 alkoxy or R10 and R11 taken together, can form with the adjacent ring, a C5-C6
cycloalkyl or C5-C6 aromatic ring;
and
m is 1 or 0.
3. A pharmaceutical composition comprising the compound as claimed in
claim 1, and a pharmaceutically acceptable carrier, such as herein described.
4. A pharmaceutical composition comprising a compound represented by the
general structure:
wherein R1 is H or halo; .
R3 is selected from the group consisting of
R10 and R11 are independently selected from the group consisting of H, halo, C1-C8
alkyl, C1-C8 haloalkyl, -NR5R7, hydroxy and C1-C8 alkoxy or R10 and R11 taken together,
can form with the adjacent ring, a C5-C6 cycloalkyl or C5-C6 aromatic ring;
R5 and R7 are independently H, or C1-C8 alkyl;
R6 is selected from the group consisting of H, or C1-C12 alkyl, C2-C8 alkenyl and
C2-C8 alkynyl;
m is an integer ranging from 0-2; and a pharmaceutically acceptable carrier, such
as herein described.
The present invention is directed to novel thalidomide derivative
compounds that have activity as anti-angiogenic compounds. More particularly the
compounds have the general structure: where R1 is selected from the group consisting
of H, halo, alkyl, haloalkyl, -NH2, hydroxy and alkoxy; R2 is selected from the group
consisting of optionally substituted bicyclic, optionally substituted aryl, and R6 is H, or
C1-C8 allcyl; R19 is optionally substituted aryl; and m is 0-6.

Documents:

1310-kolnp-2003-CORRESPONDENCE-1.1.pdf

1310-KOLNP-2003-CORRESPONDENCE.pdf

1310-KOLNP-2003-FORM 27 1.1.pdf

1310-KOLNP-2003-FORM 27.pdf

1310-KOLNP-2003-FORM-27.pdf

1310-kolnp-2003-granted-abstract.pdf

1310-kolnp-2003-granted-assignment.pdf

1310-kolnp-2003-granted-claims.pdf

1310-kolnp-2003-granted-correspondence.pdf

1310-kolnp-2003-granted-description (complete).pdf

1310-kolnp-2003-granted-examination report.pdf

1310-kolnp-2003-granted-form 1.pdf

1310-kolnp-2003-granted-form 18.pdf

1310-kolnp-2003-granted-form 3.pdf

1310-kolnp-2003-granted-form 5.pdf

1310-kolnp-2003-granted-gpa.pdf

1310-kolnp-2003-granted-reply to examination report.pdf

1310-kolnp-2003-granted-specification.pdf

1310-kolnp-2003-OTHERS.pdf


Patent Number 227743
Indian Patent Application Number 1310/KOLNP/2003
PG Journal Number 04/2009
Publication Date 23-Jan-2009
Grant Date 20-Jan-2009
Date of Filing 14-Oct-2003
Name of Patentee UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Applicant Address 1224 WEST MAIN STREET, SUITE 1-10, CHARLOTTESVILLE, VA
Inventors:
# Inventor's Name Inventor's Address
1 BROWN MILTON L 614 NETTLE COURT, CHARLOTTESVILLE, VA 22903
PCT International Classification Number C12N
PCT International Application Number PCT/US02/1265
PCT International Filing date 2002-04-02
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/285,745 2001-04-23 U.S.A.
2 60/338,955 2001-12-10 U.S.A.